Merrimen J L O, Alkhudair W K, Gupta R
Department of Anatomic Pathology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada.
Urology. 2006 May;67(5):904-9. doi: 10.1016/j.urology.2005.11.029. Epub 2006 Apr 25.
To report 9 cases of primary localized amyloidosis of the urinary tract and correlate the pathologic findings with clinical and cystoscopic information.
Patients diagnosed with amyloidosis of the ureters, urinary bladder, or urethra from 1976 to 2003 were identified. Their medical records were reviewed, and histochemical and immunoperoxidase stains were performed on the tissue.
Eight cases of amyloidosis of the urinary bladder and one of the renal pelvis/ureter were identified. None of our cases showed evidence of systemic amyloidosis. Of the 8 patients with amyloidosis of the urinary bladder, 5 presented with gross hematuria and 1 with irritative bladder symptoms and 2 had amyloidosis detected during cystoscopic follow-up for urothelial carcinoma. The patient with amyloidosis of the renal pelvis/ureter presented with flank pain and gross hematuria. The clinical impression was malignancy in 75% of the bladder cases. Most patients with bladder involvement were treated with localized bladder resection; however, 1 patient required total cystectomy for symptom control. Of 5 patients with follow-up information, 2 developed recurrence. The pathologic assessment diagnosed amyloid deposits consistent with primary or AL type amyloid in all cases. Immunoperoxidase stains revealed lymphoid cells in the vicinity of the amyloid deposits to be lambda-restricted in 78% of cases.
Primary amyloidosis of the urinary tract is a rare condition that mimics malignancy in its clinical presentation and cystoscopic appearance and on diagnostic imaging. In our study, all cases of urinary amyloid deposits represented localized amyloidosis rather than manifestations of systemic amyloidosis. Monoclonal lymphoid populations evolving from chronic inflammation in the urinary tract may be the source of the amyloid AL proteins.
报告9例原发性局限性泌尿道淀粉样变性病例,并将病理结果与临床及膀胱镜检查信息相关联。
确定1976年至2003年期间诊断为输尿管、膀胱或尿道淀粉样变性的患者。查阅他们的病历,并对组织进行组织化学和免疫过氧化物酶染色。
发现8例膀胱淀粉样变性和1例肾盂/输尿管淀粉样变性。我们的病例均未显示系统性淀粉样变性的证据。在8例膀胱淀粉样变性患者中,5例出现肉眼血尿,1例出现膀胱刺激症状,2例在膀胱镜随访尿路上皮癌时发现淀粉样变性。肾盂/输尿管淀粉样变性患者出现侧腹痛和肉眼血尿。75%的膀胱病例临床印象为恶性肿瘤。大多数膀胱受累患者接受了局部膀胱切除术;然而,1例患者为控制症状需要进行全膀胱切除术。在5例有随访信息的患者中,2例出现复发。病理评估在所有病例中均诊断为与原发性或AL型淀粉样变性一致的淀粉样沉积物。免疫过氧化物酶染色显示,78%的病例中淀粉样沉积物附近的淋巴细胞为λ限制型。
原发性泌尿道淀粉样变性是一种罕见疾病,其临床表现、膀胱镜表现及诊断性影像学表现均类似恶性肿瘤。在我们的研究中,所有泌尿道淀粉样沉积物病例均代表局限性淀粉样变性,而非系统性淀粉样变性的表现。源于泌尿道慢性炎症的单克隆淋巴细胞群体可能是淀粉样AL蛋白的来源。